January 17, 2018

ProscaVax Reduced Tumor Growth in 70% of Prostate Cancer Patients, Early-stage Study Shows

News

OncBioMune‘s investigational cancer vaccine ProscaVax reduced tumor growth in 70% of prostate cancer patients included in a Phase 1a study. The immunotherapy candidate consists of a combination of the PSA protein ... Read more

October 4, 2017

ProscaVax Vaccine Safe for Recurrent Prostate Cancer Patients, Phase 1a/1b Trial Shows

News

ProscaVax, a cancer vaccine developed by OncBioMune Pharmaceuticals, is safe for the treatment of recurrent prostate cancer patients, data from a Phase 1a/1b trial shows. The vaccine did not cause ... Read more